BioVie (BIVI) to Post Earnings on Monday

BioVie (NASDAQ:BIVI) is projected to announce its Q4 2026 results before the market opens on Monday, August 24th. Analysts expect the company to announce earnings of ($0.52) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2026 earning overview page for the latest details on the call scheduled for Thursday, August 13, 2026 at 7:00 AM ET.

BioVie (NASDAQ:BIVI) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.18).

BioVie Trading Up 4.8%

Shares of BioVie stock opened at $1.95 on Friday. The company’s 50-day moving average price is $1.67 and its 200-day moving average price is $1.50. BioVie has a 12-month low of $0.82 and a 12-month high of $3.79. The company has a market cap of $16.48 million, a price-to-earnings ratio of -0.62 and a beta of 0.60.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Prelude Capital Management LLC bought a new stake in BioVie during the third quarter valued at approximately $275,000. Prosperity Wealth Management Inc. bought a new position in shares of BioVie in the 3rd quarter worth $273,000. DRW Securities LLC bought a new position in shares of BioVie in the 4th quarter worth $149,000. Citadel Advisors LLC bought a new position in shares of BioVie in the 3rd quarter worth $199,000. Finally, Jane Street Group LLC purchased a new stake in shares of BioVie during the 2nd quarter valued at $57,000. 4.59% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

BIVI has been the subject of a number of recent analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of BioVie in a research report on Friday, July 17th. Wall Street Zen upgraded BioVie to a “sell” rating in a research report on Saturday, July 18th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, BioVie currently has a consensus rating of “Sell”.

BioVie Company Profile

BioVie Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for chronic liver diseases and associated neurological complications. The company’s research and development efforts center on candidates designed to address serious unmet medical needs in hepatic encephalopathy and other liver‐related disorders. BioVie advances its pipeline through controlled clinical trials and regulatory interactions in North America.

The company’s lead product candidate, BIV201, is undergoing Phase 2 clinical evaluation for the treatment of hepatic encephalopathy, a life‐threatening condition marked by elevated neurotoxins in patients with advanced liver disease.